Coeptis Therapeutics Holdings Inc (COEP)

The immediate narrative is one of chaotic restructuring rather than investment clarity. The stock recently underwent a reverse split and a complex merger with Z Squared, resulting in a confusing dual-ticker situation where shares were distributed as 'ZSQR' while trading under COEP. This corporate gymnastics, combined with a massive 84% drop in value over the last year and a current price hovering near the 52-week low, suggests the market is punishing the entity for its lack of substance. Fundamentally, the company is a biotech firm with no earnings, negative free cash flow, and a forward P/E that is mathematically undefined due to losses. While the gross margin looks healthy at 87%, the operating margin is deeply negative at -230%, indicating the business is burning cash without generating profit. The balance sheet shows a concerning debt-to-equity ratio of nearly 2x, and with no dividend history and a negative beta, there is no safety net for investors. The recent price action shows a temporary bounce off the lows, but given the 'VERY LOW' confidence in statistical forecasts and the absence of any credible path to profitability or a stable capital structure, the outlook remains severely bearish.